Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
During the fireside chat,
A webcast of the presentation can be accessed through the Investors section of Akebia's website at https://ir.akebia.com for approximately 90 days following the conference.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is not approved by the
Akebia Therapeutics Contact
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-hc-wainwright-kidney-conference-301880784.html